Stay updated on ADP-A2M4CD8 in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the ADP-A2M4CD8 in Ovarian Cancer Clinical Trial page.

Latest updates to the ADP-A2M4CD8 in Ovarian Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check30 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check44 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
- Check51 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.3%
- Check65 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
- Check73 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference1.0%
- Check94 days agoChange DetectedThe clinical trial ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer (SURPASS-3) has changed its status from 'Recruiting' to 'Active, not recruiting', with the new date set for 2024-12-19.SummaryDifference2%
Stay in the know with updates to ADP-A2M4CD8 in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ADP-A2M4CD8 in Ovarian Cancer Clinical Trial page.